within Pharmacolibrary.Drugs.ATC.J;

model J01FA13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01FA13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dirithromycin is a semi-synthetic macrolide antibiotic of the erythromycin family. It is a prodrug that is hydrolyzed to its active form, 9(S)-erythromycyclamine, after oral administration. It was used for the treatment of respiratory tract infections and other infections caused by susceptible bacteria, but is not widely marketed or approved in many countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Sides, GD, et al., &amp; DeSante, KA (1993). Pharmacokinetics of dirithromycin. <i>The Journal of antimicrobial chemotherapy</i> 31 Suppl C 65–75. DOI:<a href=\"https://doi.org/10.1093/jac/31.suppl_c.65\">10.1093/jac/31.suppl_c.65</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8478313/\">https://pubmed.ncbi.nlm.nih.gov/8478313</a></p></li><li><p>Wintermeyer, SM, et al., &amp; Nahata, MC (1996). Dirithromycin: a new macrolide. <i>The Annals of pharmacotherapy</i> 30(10) 1141–1149. DOI:<a href=\"https://doi.org/10.1177/106002809603001014\">10.1177/106002809603001014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8893122/\">https://pubmed.ncbi.nlm.nih.gov/8893122</a></p></li><li><p>Bachmann, K, et al., &amp; Shapiro, R (1995). The Influence of Dirithromycin on the Pharmacokinetics of Cyclosporine in Healthy Subjects and in Renal Transplant Patients. <i>American journal of therapeutics</i> 2(7) 490–498. DOI:<a href=\"https://doi.org/10.1097/00045391-199506000-00009\">10.1097/00045391-199506000-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11850697/\">https://pubmed.ncbi.nlm.nih.gov/11850697</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01FA13;
